Analyst Research Report Snapshot

Title:

Alembic Pharmaceuticals Ltd.(APL) | Q3FY13 Result Update

Price:

$46.00

Provider:

IndiaNivesh Securities Pvt Ltd

Date:

22 Jan 2013

Pages:

5

Type:

AcrobatPDF

Companies referenced:

ALEM.NS

Available for Immediate Download
Summary:

Alembic Pharmaceuticals Ltd.(APL) | Q3FY13 Result Update Revenue missed slightly, however operating performance was ahead of expectations linked with milestone payment Revenue marginally below expectations on account of lower sale from API business: APL’s Q3FY13 revenue was slightly below our estimates & de grew 3.4% y-o-y (9.2% q-o-q) to Rs 3.69 billion (V/s INSPL estimates = Rs 3.83 billion) in Q3FY13 on the back of 14.5% y-o-y growth from domestic formulations & 4% y-o-y growth from international generics partially offset by 38% decline in API business. Operating margins were ahead of expectations on account of undisclosed milestone payment: APL’s EBITDA grew 1.3% y-o-y & 7.3% q-o-q to Rs 694 million in Q3FY13 V/s INSPL est = Rs 482 million mainly due to un-disclosed milestone payments. Despite 36% q-o-q (123% y-o-y) jump in R&D expenses & increase in other operating expenses, EBITDA margins expanded 86 bps y-o-y (287 bps q-o-q) to 18.8% level (INSPL estimated ~12.6%) mainly due to milestone payment. According to management, adjusting for milestone payments, material cost was ~45% of revenue during the quarter. Hence, adjusting for that, EBITDA margins would be at 14.5% level during the quarter. Valuation: At CMP of Rs 71, the stock is trading at P/E multiple of 7.1x of FY14E & 5.5x of FY15E earnings estimates. We have recommend buy on the stock at prevailing price of Rs 49 in our “initiating coverage report released on 7th June 2012” with the target price of Rs 79, which has been already achieved. Given the recent guidance on margins front, revenue from regulated markets & new pricing policy impact, we have tweaked our numbers slightly, though overall revenue & earnings growth remains almost same during FY12-15E. Currently, by rolling over P/E multiple of 8x to FY15E, we maintain BUY on the stock with the target price of Rs 99.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.